Repair research
BPC-157 vs TB-500
Two repair peptides with distinct literature emphases.
Overview
This comparison separates BPC-157 and TB-500 for laboratory reference—not product selection.
BPC-157: Synthetic peptide derived from gastric juice protein, renowned for tissue repair, inflammation reduction, and GI protection capabilities. BPC-157 promotes blood vessel formation, e…
TB-500: A synthetic 7-amino acid fragment corresponding to the actin-binding region of thymosin beta-4, originally developed for equine use with retained tissue repair properties. TB-500 a…
Key differences
- BPC-157 literature emphasises GI cytoprotection, angiogenesis, and localized repair models.
- TB-500 literature emphasises actin-related cell migration and thymosin β4 fragment biology.
Mechanistic differences
BPC-157: Synthetic peptide derived from gastric juice protein, renowned for tissue repair, inflammation reduction, and GI protection capabilities. BPC-157 promotes blood…
TB-500: A synthetic 7-amino acid fragment corresponding to the actin-binding region of thymosin beta-4, originally developed for equine use with retained tissue repair…
Pharmacology
BPC-157: Pharmacokinetic detail should be read from primary literature.
TB-500: Pharmacokinetic detail should be read from primary literature.
Research focus
BPC-157: Tissue repair & recovery: Synthetic peptide derived from gastric juice protein, renowned for tissue repair, inflammation reduction, and GI protection capabilities. BPC-15…
TB-500: Tissue repair & recovery: A synthetic 7-amino acid fragment corresponding to the actin-binding region of thymosin beta-4, originally developed for equine use with retaine…
At a glance
Practical differentiation
- AXIOM does not provide dosing, administration, or protocol guidance.
- Catalogue links appear only where AXIOM lists a research-use product.
- Reference-only compounds remain comparison terms without implying availability.
References
- pubmed.ncbi.nlm.nih.gov/39325560/
- pubmed.ncbi.nlm.nih.gov/32334036/
- pubmed.ncbi.nlm.nih.gov/40131143/
- pubmed.ncbi.nlm.nih.gov/27847966/
- pubmed.ncbi.nlm.nih.gov/14554208/
- pubmed.ncbi.nlm.nih.gov/32445447/
- pubmed.ncbi.nlm.nih.gov/31266512/
- pubmed.ncbi.nlm.nih.gov/16609979/
FAQ
Does this page recommend BPC-157 or TB-500?
No. It is an editorial comparison for research context only.
Does AXIOM provide protocol guidance?
No. Protocol and dosing decisions belong with qualified laboratory teams and source literature.